Most of Big Pharma has left the building when it comes to antimicrobial drug development, and small companies with newly approved antibiotics are struggling to stay afloat. Meanwhile, the foundation arm of Pfizer $PFE is offering its support, in the form of grants for NGO and social enterprises that are working on addressing this major health challenge: antimicrobial resistance. Recipients of the one-year Global Health Innovation Grants include partners in 12 low- and middle-income countries who will each receive $100,000.
Eiger BioPharmaceuticals $EIGR is scrapping one of its mid-stage programs for pulmonary arterial hypertension after their Phase II trial for ubenimex failed on several key fronts.